Penningtons Manches Cooper advises Accession Therapeutics on £30.5 million Series A funding
The corporate team at Penningtons Manches Cooper has advised Accession Therapeutics, a UK-based clinical-stage biotechnology company pioneering targeted immunotherapies for cancer, on its £30.5 million Series A financing round.
The investment will accelerate development of its proprietary Trocept platform, designed to deliver potent immune responses directly to solid tumours.
Accession Therapeutics, headquartered in Oxford, is focused on transforming cancer treatment through precision immunotherapy. The Trocept platform uses engineered viral vectors to selectively target tumour cells, aiming to overcome limitations of current immunotherapies and improve patient outcomes.
The investment round, led by a syndicate of experienced life sciences investors, will enable Accession Therapeutics to advance its pipeline of novel immunotherapies. This significant funding reflects strong confidence in the company’s science and its potential to redefine cancer care.
The team at Penningtons Manches Cooper was led by corporate partner, James Went, with support from corporate tax partner Kathy Potter and senior associate Leonie Langley, and trainee solicitor Alec Cumming.
Nick Cross, co-founder and chairman at Accession Therapeutics, commented: “This significant investment validates our innovative approach and will enable us to progress in advancing the TROCEPT pipeline. We are excited to work with our investors to bring new hope to patients battling solid tumours. We highly value the long term support provided by Penningtons Manches Cooper and their role in completing this funding round.”
James Went, partner at Penningtons Manches Cooper, added: “Having supported Accession Therapeutics from day one, we are delighted to have worked with them to take this significant step. They have a fantastic team, cutting-edge science and ambitious growth plans making them a very exciting biotechnology company to work with.”